U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
about
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsQuantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case reportOverall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancerMutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFRHarnessing plasma genotyping for precision therapy against lung cancer.Metastatic lung cancer in the age of targeted therapy: improving long-term survival.Pinus massoniana bark extract inhibits migration of the lung cancer A549 cell line.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Addressing the right targets in oncology: challenges and alternative approaches.Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.Discovery of a potent dual ALK and EGFR T790M inhibitor.Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature.Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patients with Del19/L858R.The Pitfalls of Companion Diagnostics: Evaluation of Discordant EGFR Mutation Results from a Clinical Laboratory and a Central Laboratory.Urine test for EGFR analysis in patients with non-small cell lung cancer.Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.
P2860
Q26778318-C1269711-DE4A-4A6D-92E4-395DA90FF9DBQ28079320-5F2EFA2C-96D7-45DA-93A6-1BB7D8C64CD0Q28086768-B1EF49A0-9E90-4ED8-9C44-D6603D1E1414Q33914197-3A14773E-B31A-47C9-8DBA-DA6177CC6040Q33967404-1BC5FFC3-7DBF-4E23-A5A0-59B82AB9EB40Q35168766-0C65C364-29D6-4877-8872-9BA3D47C1D5DQ35870274-8A1E9A7E-FD93-47D5-801A-167B6963A9BDQ36270116-718047C1-F624-4CAB-B5F1-B69E1F5D0AB0Q37051546-1A8B3EE2-0BD7-45F4-8301-54F0362E476EQ37086009-5BFD59E9-7047-4C16-A53A-CA4F5B176333Q37411128-FFA3F68A-A2E3-460A-9EA1-E0D745913474Q37584403-BE2D4430-81B7-4B97-A092-A2C5CB924D7CQ37701239-6E351B1D-5826-450F-992A-3E498AB1D27AQ38262804-2E63ACF4-75B3-4025-9A93-064ECAC33525Q38329647-E62B9202-61F5-43B5-A02B-45D73981D5AFQ38670719-1DCC7D62-F5AB-4260-8562-C1FE8E3A75D7Q38702793-212A5CB9-928E-426E-A40D-BE3C9E39E879Q38856978-109E6C4B-CC51-4EFE-B484-C42B60127783Q38880510-120A72A1-0B95-4766-9C99-49B3ED832289Q38882266-E1101FCA-6B4F-4100-900E-851E3D969F3EQ38982119-63451ED7-1D22-4170-8DDE-35F47A67F602Q40996798-203035AA-C0D7-4D77-8BBB-79E34BF7EEA3Q42328292-BCC649D5-35BC-4213-AADE-33BA2E7AC8D3Q42414610-94BAEB4A-B34E-4462-AE87-71052F31A8D9Q47139220-6BCC1D1D-33D3-4063-9758-887A5C0FDC54Q47564108-7EC7956A-11B6-47C9-9E39-893C91EC4F66Q47746017-975BE459-1B2F-4897-B458-8B5F7AE4D013Q47897098-27B071C8-DF2B-4092-AD52-F4574B5D5FDBQ49787333-5D2FBD5D-7F68-4A0F-A478-363D25517C42Q52673089-E2C94D7A-23DB-4C8D-ACE5-4C95DF3FFE89
P2860
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@ast
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@en
type
label
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@ast
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@en
prefLabel
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@ast
U.S. Food and Drug Administrat ...... L858R) substitution mutations.
@en
P2093
P2860
P1433
P1476
U.S. Food and Drug Administrat ...... (L858R) substitution mutations
@en
P2093
Anthony Murgo
Gideon M Blumenthal
Karen Boyd
Patricia Keegan
Richard Pazdur
Robert Justice
Xiaoping Jiang
P2860
P304
P356
10.1634/THEONCOLOGIST.2014-0089
P50
P577
2014-05-27T00:00:00Z